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PNovel Approaches for Preventing
or Limiting Events (Naples) II Trial
Impact of a Single High Loading Dose
of Atorvastatin on Periprocedural Myocardial Infarction
Carlo Briguori, MD, PHD,*† Gabriella Visconti, MD,* Amelia Focaccio, MD,* Bruno Golia, MD,*
Alaide Chieffo, MD,† Alfredo Castelli, MD,† Marco Mussardo, MD,† Matteo Montorfano, MD,†
Bruno Ricciardelli, MD,* Antonio Colombo, MD†
Naples and Milan, Italy
Objectives Atorvastatin administered at least 7 days before the percutaneous coronary intervention (PCI) reduces the rate
of periprocedural myocardial infarction (MI). It is unknown whether a single, high (80 mg) loading dose of atorva-
statin may reduce the rate of periprocedural MI.
Background Periprocedural MI is a prognostically important complication of PCI.
Methods The day before the elective PCI, 668 statin-naive patients were randomly assigned to atorvastatin 80 mg (ator-
vastatin group; n  338) or no statin treatment (control group; n  330). Creatine kinase-myocardial isoenzyme
(CK-MB) (upper limit of normal [ULN] 3.5 ng/ml) and cardiac troponin I (ULN 0.10 ng/ml) were assessed before
and 6 and 12 h after the intervention. Periprocedural MI was defined as a CK-MB elevation 3 ULN alone or
associated with chest pain or ST-segment or T-wave abnormalities.
Results The incidence of a periprocedural MI was 9.5% in the atorvastatin group and 15.8% in the control group (odds
ratio: 0.56; 95% confidence interval: 0.35 to 0.89; p  0.014). Median CK-MB peak after PCI was 2.10 ng/ml
(interquartile range 1.00 to 12.50 ng/ml) in the atorvastatin group and 3.20 ng/ml (interquartile range 1.37 to
16.07 ng/ml) in the control group (p  0.014). The incidence of cardiac troponin I elevation 3 ULN was
26.6% in the atorvastatin group and 39.1% in the control group (odds ratio: 0.56; 95% confidence interval:
0.40 to 0.78; p  0.001).
Conclusions A single, high (80 mg) loading (within 24 h) dose of atorvastatin reduces the incidence of periprocedural MI in
elective PCI. (J Am Coll Cardiol 2009;54:2157–63) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.005p
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dn increase in cardiac biomarkers has been shown to occur
n 5% to 30% of patients after otherwise successful percu-
aneous coronary interventions (PCIs) (1). This elevation of
ardiac enzymes is indicative of cell death and, according to
he new criteria, should be labeled as a myocardial infarction
MI) (1,2). At present, a creatine kinase-myocardial isoen-
yme (CK-MB) elevation 3 normal has been recom-
ended as a cutoff for periprocedural MI after PCI (1–3). It
as been demonstrated that the risk of subsequent cardiac
vents (death or MI) is related to the extent of cardiac
roponin or CK-MB increase (4,5).
rom the *Laboratory of Interventional Cardiology and Department of Cardiology,
linica Mediterranea, Naples, Italy; and the †Laboratory of Interventional Cardiol-
gy, “Vita e Salute” University School of Medicine, San Raffaele Scientific Institute,
ilan, Italy. Dr. Colombo is a minor shareholder of Cappella Inc.t
Manuscript received May 18, 2009; revised manuscript received June 25, 2009,
ccepted July 1, 2009.Different strategies have been proposed and tested to
revent periprocedural MI (6–8). Compelling data suggest
hat 3-hydroxy-3-methylglutaryl coenzyme A reductase in-
ibitors (statins) may reduce the rate of periprocedural MI
9–12). The available data suggest that statin administration
hould be started at least 3 to 7 days before the procedure
9,10). This implies the need to postpone PCI in all
tatin-naive patients. Due to the fact that this beneficial
See page 2164
ffect of statins seems to be because of their “pleiotropic”
ffect, independent from cholesterol reduction (13–15),
e hypothesized that a high (80 mg) loading dose of
torvastatin administered within 24 h before the proce-
ure may be effective in reducing the rate of periproce-
ural MI. Therefore, we conducted a 2-center, prospec-
ive randomized study to assess whether a single, high (80
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Statin and Periprocedural MI December 1, 2009:2157–63mg) loading (within 24 h) dose
of atorvastatin is effective in
preventing elevation of biomar-
kers of MI after elective coro-
nary stent implantation.
Methods
Patient population. From Jan-
uary 2005 to December 2008,
668 naive (i.e., not taking statin)
patients scheduled for: 1) elective
coronary angiography due to
symptomatic coronary artery dis-
ease; or 2) PCI in de novo lesions
in native coronary arteries were
onsidered eligible for the study. The day before the
rocedure, all eligible patients were randomly assigned to
torvastatin treatment (atorvastatin group) or to no atorva-
tatin treatment (control group). Randomization was per-
ormed by a 1:1 ratio using computer-generated random
umbers. To ensure that an almost equal number of patients
eceived 1 of the 2 treatments, a randomization block of 4
as used (Plan Procedure of SAS, version 8.2, SAS Inc.,
ary, North Carolina). The local ethics committee ap-
roved the study, and all patients gave written informed
onsent.
CI procedure. Stents were implanted according to cur-
ent clinical practice. Angiographic success was defined as a
nal angiographic residual stenosis of 20% by visual
stimation. Procedural success was considered in cases of
ngiographic success and absence of any in-hospital major
Figure 1 Flow Chart of the Study
Diagram showing the flow of participants through each stage of the trial.
CABG  coronary artery bypass grafting; ISR  in-stent restenosis; PCI  percuta
Abbreviations
and Acronyms
CI  confidence interval
CK-MB  creatine kinase-
myocardial isoenzyme
CRP  C-reactive protein
cTnI  cardiac troponin I
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous
coronary intervention
ULN  upper limit of
normalomplication (acute MI, need for bypass surgery or repeat
CI, or death). All patients received daily aspirin long-life
100 mg/day) and clopidogrel 300 mg the previous day
ollowed by daily administration of 75 mg for at least 30
ays after PCI in case of bare-metal stent implant or at least
months in case of drug-eluting stent implant. Patients
andomized in the atorvastatin group started statin treat-
ent (loading dose atorvastatin 80 mg) within 24 h before
tent deployment. All patients received a 70-IU/kg intrave-
ous bolus of unfractionated heparin. Additional heparin
oluses were given to maintain activated clotting time250 s.
he activated clotting time was measured on the ACT
LUS Automated Coagulation Timer System (Medtronic
ascular Inc., Santa Rosa, California) 5 min after heparin
dministration.
Glycoprotein IIb/IIIa inhibitors were administered ac-
ording to operator preference. The occurrence of angio-
raphic complications during PCI was recorded. Angio-
raphic complications included minor/major side branch
ompromise or occlusions, abrupt intraprocedural vessel
losure, major arterial dissection, thrombus formation, tran-
ient and/or prolonged slow-no reflow, distal embolization,
r coronary perforation.
ost-procedure management and follow-up. Aspirin
325 mg/day) and clopidogrel (75 mg daily for 30 days) were
rescribed to all patients. All patients were discharged on
tatins (atorvastatin 20 mg/day). CK-MB (mass concentra-
ion) and cardiac troponin I (cTnI) were assessed before, 6
nd 12 h after PCI using a radioimmunoassay analyzer
Stratus CS-STAT Fluorometric Analyzer, Dade Behring
arburg GmbH, Marburg, Germany). Additional samples
coronary intervention.neous
w
m
n
n
r
w
C
t
G
i
C
(
S
t
t
S
M
1
c
a
S
o
t
U
o
p
o
D
d
d
C
o
e
M
f
c
t
s
f
a
ssel an
2159JACC Vol. 54, No. 23, 2009 Briguori et al.
December 1, 2009:2157–63 Statin and Periprocedural MIere obtained if the patient developed signs or symptoms of
yocardial ischemia. CK-MB mass and cTnI upper limit of
ormal (ULN) levels were 3.5 ng/ml (range 0.6 to 3.5
g/ml) and 0.10 ng/ml (range 0.00 to 0.10 ng/ml),
espectively. Abnormal baseline CK-MB and/or cTnI levels
ere exclusion criteria for enrollment into the study. Plasma
-reactive protein (CRP) levels were assessed the day before
he PCI by the RapiTex CRP (Dade Behring Marburg
mbH). This was a semiquantitative test. It is based upon the
mmunochemical reaction between CRP and antibodies to
RP bound to latex particles. Elevated CRP concentration
6 mg/l) leads to visible agglutination of the latex particles.
tudy end point. The primary end point of the study was
he rate of periprocedural MI, defined as a CK-MB eleva-
ion 3 ULN alone or associated with chest pain or
T-segment or T-wave abnormalities (new definition of
I), in the 2 study groups. The secondary end points were:
) the rate of cTnI elevation 3 ULN; and 2) the
omposite of all the in-hospital events, including death, MI,
nd repeated revascularization.
Clinical Characteristics of the Patients EnrolledTable 1 Clinical Characteristics of the Patie
Atorv
Age (yrs)
Men 2
Symptoms
Asymptomatic
Stable angina 2
Unstable angina
Family history of coronary artery disease 1
Body mass index, kg/m2 2
Diabetes mellitus 1
Left ventricular ejection fraction, % 5
Previous myocardial infarction 1
Previous bypass surgery
Previous PCI*
Systemic hypertension 2
Active smokers
Beta-blockers 1
*Percutaneous coronary intervention (PCI) performed in a different ve
Biochemical Characteristics of the Patients EnrTable 2 Biochemical Characteristics of the
Atorvast
(n 
Serum creatinine, median (IQR) 1.16 (1
GFR (ml/min/1.73 m2) 65
GFR 60 ml/min/1.73 m2, n (%) 124 (3
Fibrinogen, mg/dl 379
Lipids, mg/dl
Total cholesterol 211
LDL-C 126
HDL-C 48
Triglycerides 159GFR glomerular filtration rate; HDL-C high-density lipoprotein cholesterol;tatistical analysis. The sample size was selected to dem-
nstrate a reduction in the primary end point from 15% in
he control group to 8% in the atorvastatin group (9,10).
sing a chi-square test for 2  2 tables and a 2-sided alpha
f 0.05, 650 randomized patients afforded the study 80%
ower. Continuous variables are presented as mean  1 SD
r as median and interquartile ranges, as appropriate.
ifferences between groups in normally and non-normally
istributed variables were assessed using the unpaired Stu-
ent t test and the Mann-Whitney U test, respectively.
ategorical variables were analyzed by chi-square test. In
rder to test whether CRP at baseline may impact the
ffectiveness of atorvastatin treatment on periprocedural
I, we used an analysis of covariance model after trans-
orming CK-MB levels into a natural logarithm (to over-
ome the problem of the non-normal distribution), putting
he peak log-CK-MB as the dependent variable, treatment
trategy (as defined by protocol randomization) as a fixed
actor, baseline log-CK-MB as a covariate, and CRP levels
s a random factor. Furthermore, we tested the interaction
e 2 Groupsnrolled in the 2 Groups
in Group
38)
Control Group
(n  330) p Value
9 65 10 0.20
.7%) 263 (79.7%) 0.85
0.62
.3%) 34 (10.3%)
.3%) 288 (87.3%)
%) 8 (2.4%)
%) 112 (34%) 0.28
3.8 27.4 3.5 0.26
.6%) 121 (36.8%) 0.72
9.5 55.5 9.9 0.58
.4%) 97 (29.4%) 0.56
%) 27 (8.1%) 0.66
.1%) 31 (9.4%) 0.36
.5%) 245 (74.2%) 0.47
%) 66 (20%) 0.28
.5%) 129 (39.1%) 0.93
d/or lesion.
in the 2 Groupsnts Enrolled in the 2 Groups
roup Control Group
(n  330) p Value
32) 1.18 (1.00–1.35) 0.73
64 19 0.47
140 (42.4%) 0.15
363 100 0.51
210 42 0.59
129 37 0.27
48 12 0.48
151 88 0.32in thnts E
astat
(n  3
64
66 (78
45 (13
85 (84
8 (2.4
01 (30
7.8
30 (38
5.7
13 (33
24 (7.1
41 (12
45 (72
79 (24
30 (38olledPatie
atin G
338)
.00–1.
 17
6.6%)
 123
 46
 35
 11
 88IQR interquartile range; LDL-C low-density lipoprotein cholesterol.
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Statin and Periprocedural MI December 1, 2009:2157–63etween atorvastatin therapy and the usage of glyco-
rotein IIb/IIIa inhibitors by the Cochran’s Q test. All
robability values were 2-tailed and a value of p  0.05
as considered significant. Data were analyzed with
PSS for Windows version 13.0 (SPSS Inc., Chicago,
llinois).
esults
linical characteristics. Between January 2005 and De-
ember 2008, 1,385 patients not taking statin (statin naive)
nd scheduled for elective coronary angiography or angio-
Angiographic Characteristics of the Patients EnTable 3 Angiographic Characteristics of the
Atorva
(n
Distribution of coronary artery disease
Single-vessel 12
Double-vessel 12
Triple-vessel 8
Vessel treated
LAD 18
LCx 7
RCA 10
Left main
Lesion site
Ostial 4
Proximal 19
Mid-vessel 16
Distal 3
Number of treated vessels/patient 1
Number of treated lesions/patient 1
Multivessel PCI 3
Complex lesions (B2/C) 17
Diameter stenosis, %
Pre-procedure 8
Post-procedure
Reference vessel diameter, mm
Pre-procedure 3.1
Post-procedure 3.3
Minimal lumen diameter, mm
Pre-procedure 0.5
Post-procedure 3.3
Bifurcation lesions 5
Thrombus
Calcification 8
Chronic total occlusion 6
Lesion length, mm 1
Pre-procedural TIMI flow grade
0/1 5
2/3 28
Post-procedural TIMI flow grade
0/1
2/3 33
Stent length (mm) 3
Balloon-to-artery ratio 1.0
Maximum pressure inflation (atm) 1LAD  left anterior descending artery; LCx  left circumflex artery; PCI  per
Thrombolysis In Myocardial Infarction.lasty in our institutions were recruited for this study and
andomized into the 2 groups of treatment. Approximately
ne-half of these patients were eventually excluded due to
ack of satisfaction of final inclusion criteria (i.e., PCI and
tent implantation in a de novo lesion in a native coronary
rtery) (Fig. 1). Therefore, 668 patients were included in the
nal analysis: 338 in the atorvastatin group and 330 in the
ontrol group (Fig. 1). There were no significant differences
n the most relevant clinical characteristics in the 2 groups
Table 1). Total cholesterol and low-density cholesterol
evels at the time of the procedure were similar in the 2
in the 2 Groupsents Enrolled in the 2 Groups
Group
8)
Control Group
(n  330) p Value
0.80
%) 125 (37.9%)
%) 117 (35.5%)
%) 88 (26.6%)
366 0.74
%) 185 (50.5%)
%) 71 (19.4%)
%) 105 (28.5%)
) 6 (1.6%)
426 0.24
%) 47 (11%)
%) 189 (44.4%)
%) 172 (40.4%)
) 18 (4.2%)
.5 1.1 0.3 0.67
.6 1.3 0.6 0.86
) 33 (10%) 0.74
%) 177 (53.7%) 0.93
2 84 13 0.44
2 3 0.15
.62 3.23 0.59 0.21
.61 3.37 0.58 0.54
.44 0.51 0.40 0.78
.61 3.41 0.60 0.41
%) 55 (16.6%) 0.84
) 9 (2.7%) 0.44
%) 88 (26.8%) 0.55
%) 59 (17.9%) 0.69
0 19 8 0.50
0.71
) 54 (16.5%)
) 276 (83.5%)
0.68
) 0 (0%)
%) 330 (100%)
6 30 16 0.87
.12 1.03 0.09 0.25
15 4 0.93rolledPati
statin
 33
8 (37.9
1 (35.8
9 (26.3
371
6 (50.1
2 (19.5
7 (28.8
6 (1.6%
436
6 (10.7
3 (44.2
1 (36.9
5 (8.2%
.1 0
.3 0
7 (11%
3 (51.3
5 1
2 6
6 0
4 0
1 0
6 0
6 (16.7
6 (1.7%
0 (23.7
4 (18.9
8 1
4 (16%
4 (84%
1 (0.3%
7 (99.7
0 1
5 0
5 4cutaneous coronary intervention; RCA  right coronary artery; TIMI 
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December 1, 2009:2157–63 Statin and Periprocedural MIroups (Table 2). At the time of the PCI, the rate of high
evels of CRP was similar in the 2 groups (25.4% in the
torvastatin group versus 29.4% in the control group; p 
.31). There were no instances of a significant increase in
erum liver enzymes (alanine aminotransferase and aspartate
Figure 2 CK-MB Increase in the 2 Treatment Groups
(A) Incidence of creatine kinase-myocardial isoenzyme (CK-MB) increase 3
the upper limit of normal (ULN) in the atorvastatin group and in the control
group. (B) Incidence of CK-MB increase 3 ULN in the subgroup of patients
with normal and high C-reactive protein (CRP) in both the atorvastatin group
and in the control group. CI  confidence interval; OR  odds ratio.
ngiographic Complicationsf the P tients Enrolled in the 2 GroupsTable 4 Angiograph c Complicationsof the Patients Enrolled in the 2 Groups
Atorvastatin Group
(n  338)
Control Group
(n  330) p Value
Major dissection 2 (0.59%) 3 (0.90%) 0.68
Abrupt closure 1 (0.29%) 0 0.49
Slow/no reflow 2 (0.59%) 8 (2.40%) 0.06
Thrombus formation 2 (0.59%) 0 0.50
Side-branch closure/
compromise
5 (1.48%) 7 (2.12%) 0.57
Distal embolization 2 (0.59%) 2 (0.60%) 1.00
Coronary perforation 2 (0.59%) 2 (0.60%) 1.00
Any of the above 16 (4.7%) 22 (6.6%) 0.31iminotransferase levels3 ULN) and/or myopathy in the
torvastatin group.
ngiographic and procedural characteristics. Direct
tenting was performed in 28.5% of cases in the atorvastatin
roup and in 30.3% in the control group (p  0.51).
irectional or rotational atherectomy was performed in
.5% of the subjects in the atorvastatin group and in 2.1% of
he subjects in the control group (p  0.54). All the other
ngiographic and procedural characteristics were similar in
he 2 groups (Table 3). Glycoprotein IIb/IIIa inhibitors
ere administered in 43 of 338 patients (12.7%) in the
torvastatin group and in 46 of 330 patients (13.6%) in the
ontrol group (p  0.65). Angiographic complications
uring the procedure occurred in 16 patients (4.7%) in the
torvastatin group and in 22 patients (6.6%) in the control
roup (p  0.61; odds ratio [OR]: 086; 95% confidence
Figure 3 Troponin I Increase in the 2 Treatment Groups
(A) Incidence of troponin I (TnI) increase 3 ULN in the atorvastatin group
and in the control group. (B) Incidence of TnI increase 3 ULN in the sub-
group of patients with normal and high CRP in both the atorvastatin group and
in the control group. Abbreviations as in Figure 2.nterval [CI]: 0.48 to 1.52) (Table 4).
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Statin and Periprocedural MI December 1, 2009:2157–63ardiac markers increase. The incidence of a CK-MB
levation 3 ULN was 9.5% (32 of 338) in the atorva-
tatin group and 15.8% (52 of 330) in the control group
OR: 0.56; 95% CI: 0.35 to 0.89; p 0.014) (Fig. 2A). The
ncidence of cTnI elevation 3 ULN was 26.6% (90 of
38) in the atorvastatin group and 39.1% (129 of 330) in the
ontrol group (OR: 0.56; 95% CI: 0.40 to 0.78; p  0.001)
Fig. 3A). Additional data on the changes in cardiac
nzymes after PCI in the 2 groups are reported in Table 5.
post hoc analysis suggests that the cardioprotective effect
f atorvastatin was more pronounced in the subgroup of
atients with high CRP levels at baseline (Figs. 2 and 3B).
ndeed, there was a significant interaction between treat-
ent strategy and CRP levels at baseline (F  8.12, p 
.004 by the analysis of covariance model). On the contrary,
o evidence of statistical interaction between atorvastatin
herapy and usage of glycoprotein IIb/IIIa inhibitors was
ound at analytical testing (p  0.62).
n-hospital major adverse cardiac events. Acute stent
hrombosis occurred in 2 cases in the atorvastatin group
0.58%) and in 1 case in the control group (0.30%) (p 
.57). In-hospital death occurred in 1 case in the atorvasta-
in group, due to coronary perforation complicated by
ardiac tamponade and Q-wave MI. No case of urgent
n-hospital repeated revascularization was observed. The
omposite end point of all in-hospital events (death, MI,
nd repeated revascularization) occurred in 34 of 338
atients (10%) in the atorvastatin group versus 52 of 330
15.7%) in the control group (p 0.029; OR: 0.63; 95% CI:
.39 to 0.95).
iscussion
his randomized study demonstrated that a single high (80
g) loading dose of atorvastatin administered within 24 h
efore stenting is effective in reducing the rate of peripro-
edural MI. This result confirms previous observations
emonstrating that statins prevent MI after coronary stent
mplantation. However, in the previous studies, statin ad-
inistration was started at least 3 to 7 days before the
rocedure (9,10). The effectiveness of a single high (80 mg)
oading dose of atorvastatin administered within 24 h before
hanges in Cardiac Enzymes AfterCI in the Patients rolled in the 2 GroupsTable 5 Cha ges in Cardiac Enzymes AfterPCI in the Patients Enrolled in the 2 Groups
Atorvastatin Group
(n  338)
Control Group
(n  330) p Value
CK-MB peak, pg/ml* 2.10 (0.10–12.50) 3.20 (1.27–16.07) 0.014
Any CK-MB increase
above ULN, %
23 37 0.001
TnI peak, pg/ml* 0.10 (0.03–0.54) 0.20 (0.05–0.73) 0.004
Any TnI increase
above ULN, %
42 52.6 0.001
Median (interquartile range).
CK-MB  creatine kinase-myocardial isoenzyme; PCI  percutaneous coronary intervention;
nI  cardiac troponin I; ULN  upper limit of normal.tenting extends our knowledge of the cardioprotective offect of statin, overturning the need to postpone PCI in all
tatin-naive patients undergoing an elective coronary pro-
edures. Although the majority of patients undergoing an
lective coronary procedure are on statin therapy, the
roportion of statin-naive patients is not trivial. In our
xperience, during the recruitment time period of the present
rial, statin-naive patients undergoing elective coronary proce-
ures encompassed approximately 10% of the global popula-
ion. This proportion was significantly higher (31%) in the
ecently presented ARMYDA-RECAPTURE (Atorvastatin
or Reduction of Myocardial Damage during Angioplasty)
rial (16).
The present study was not designed to clarify the poten-
ial mechanism(s) of the cardioprotective effect of the
tatins. Previous studies suggest the benefits of statins in
educing the rate of periprocedural MI should be mostly
elated to their nonlipid-related mechanisms (so-called
pleiotropic effects”). The pleiotropic effects encompass
everal mechanisms that modify inflammation responses,
ndothelial function, plaque stability, and thrombus forma-
ion (13–15,17–21). Notably, both the anti-inflammatory
nd the endothelial effects may occur immediately after a
ingle dose of statin. Ostadal et al. (22), indeed, demon-
trated that a single dose of cerivastatin at the time of
dmission of patients with unstable angina or non–ST-
egment elevation MI positively influences the inflamma-
ory parameters of CRP and interleukin-6 at 24 h. Romano
t al. (23) observed that a 24-h treatment with lovastatin
nd simvastatin induces inhibition of monocyte chemotactic
rotein-1 synthesis in mononuclear and endothelial cells in
itro. The reduction of interleukin-6 mRNA and protein
as described after 6 to 24 h of incubation of endothelial
ells with pravastatin, simvastatin, and fluvastatin in vitro
24). Our observation that the beneficial effect seems to be
uch more prevalent in the subgroup of patients with
aseline high CRP supports the concept that the anti-
nflammatory properties have an important role. However,
he immediate positive effect on endothelial function may
epresent a further mechanism. Statins indeed have benefi-
ial effects on endothelial function by a rapid increase in
itric oxide bioavailability; this effect has been observed as
arly as 3 h after statin administration (25). Nitric oxide has
een shown to act as a physiological inhibitor of leukocyte-
ndothelial cell interaction by suppressing up-regulation
f several endothelial cell adhesion molecules, including
-selectin, vascular cell adhesion molecule-1, and inter-
ellular adhesion molecule-1 (26). Statins attenuated
eutrophil-endothelium interaction in the coronary micro-
asculature (27,28). Furthermore, a brief (10-min) exposure
f the normo-cholesterolemic adult heart to atorvastatin,
fter a period of injurious ischemia, recruits the phos-
hatidyl inositol 3-kinase pathway, leading to cardioprotec-
ion (29).
tudy limitations. The study was not blinded. We can
nly speculate on the possible cardioprotective mechanisms
f a single, high loading dose of atorvastatin. Indeed, we did
n
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December 1, 2009:2157–63 Statin and Periprocedural MIot assess CRP at 24 to 48 h after atorvastatin administra-
ion, nor did we dose other inflammatory markers, such as
nterleukin-6 and monocyte chemotactic protein-1. Fur-
hermore, we did not assess endothelial function either
efore or after atorvastatin administration. The use of
Ib/IIIa inhibitors and beta-blockers was not randomized:
his may have influenced our results. However, we did not
nd any interaction between atorvastatin administration and
se of IIb/IIIa inhibitors. Finally, although not statistically
ifferent, the proportion of high-risk patients (i.e., chronic
idney disease) and the rate of angiographic complications
as numerically higher in the control group.
onclusion
his randomized study supports the cardioprotective effect
f a single high (80 mg) loading dose of atorvastatin
dministered within 24 h before stent implantation.
eprint requests and correspondence: Dr. Carlo Briguori, Inter-
entional Cardiology, Clinica Mediterranea, Via Orazio, 2, I-80121,
aples, Italy. E-mail: carlobriguori@clinicamediterranea.it.
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